Case-Western Reserve University, Cleveland, Ohio.
George Washington University, Rockville, Maryland.
Pediatr Diabetes. 2019 Sep;20(6):743-749. doi: 10.1111/pedi.12877. Epub 2019 Jul 9.
Case series and registry data suggest that diabetic retinopathy requiring treatment is rare in youth with type 1 diabetes (T1D) prior to 18 years of age. We evaluated this question in the standardized clinical trial setting by retrospectively reviewing diabetic retinopathy examinations from participants in the Diabetes Control and Complications Trial (DCCT) who were 13 to <18 years of age at randomization. Standardized stereoscopic 7-field fundus photographs were obtained every 6 months during DCCT (1983-1993). Photographs were graded centrally using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Transitions in diabetic retinopathy status over time were described. A total of 195 participants with median baseline glycated hemoglobin (HbA1c) of 9.3% (103 in the conventional and 92 in the intensive treatment groups) had an average of 5.3 diabetic retinopathy assessments during 2.3 years of follow-up (range 1-11) while under 18 years of age during the DCCT. No participant developed severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and only one participant (in the intensive group) reached clinically significant macular edema (CSME) while less than 18 years of age. In this incident case, baseline characteristics included diabetes duration 9.3 years, HbA1c 10.3%, LDL 131 mg/dL, and mild non-proliferative diabetic retinopathy (35/35 ETDRS scale); CSME resolved without treatment. Similar analyses using age cut-offs of <19, 20, or 21 years showed a slight rise in diabetic retinopathy requiring treatment over late adolescence. Clinical trial evidence suggests that frequent eye exams may not be universally necessary in youth <18 years of age with T1D.
病例系列和注册数据表明,18 岁以下的 1 型糖尿病(T1D)患者很少出现需要治疗的糖尿病视网膜病变。我们通过回顾性分析糖尿病控制和并发症试验(DCCT)中年龄在 13 至<18 岁之间的随机分组参与者的糖尿病视网膜病变检查,在标准化临床试验环境中评估了这一问题。在 DCCT 期间(1983-1993 年),每 6 个月进行一次标准化的立体 7 视野眼底照相。使用早期糖尿病视网膜病变研究(ETDRS)量表对照片进行中心分级。描述了随时间推移糖尿病视网膜病变状态的转变。共有 195 名基线糖化血红蛋白(HbA1c)为 9.3%的参与者(常规治疗组 103 名,强化治疗组 92 名),在接受 DCCT 治疗期间平均进行了 5.3 次糖尿病视网膜病变评估,随访时间为 2.3 年(范围 1-11),年龄均小于 18 岁。没有参与者发展为严重非增殖性糖尿病视网膜病变或增殖性糖尿病视网膜病变,只有一名参与者(强化治疗组)在年龄小于 18 岁时出现临床显著黄斑水肿(CSME)。在这一偶发病例中,基线特征包括糖尿病病程 9.3 年、HbA1c 10.3%、LDL 131mg/dL 和轻度非增殖性糖尿病视网膜病变(35/35 ETDRS 量表);CSME 未经治疗而缓解。使用年龄截止值<19、20 或 21 岁进行的类似分析表明,青少年后期需要治疗的糖尿病视网膜病变略有增加。临床试验证据表明,在年龄小于 18 岁的 T1D 青少年中,频繁的眼部检查可能不是普遍必要的。